Latigo Biotherapeutics Inc. (NASDAQ: LTGO) Stock Competitors & Peer Comparison
See LTGO's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Pharmaceuticals Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for LTGO and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| LTGO | $12.60 | -3.15% | 756.1M | -4.99 | -$2.52 | N/A |
| RPRX | $67.30 | -0.40% | 30B | 12.82 | $5.25 | +1.38% |
| WBA | $11.98 | +0.50% | 10.4B | -1.64 | -$7.29 | +4.17% |
| CORT | $72.77 | +1.59% | 7.9B | 207.83 | $0.35 | N/A |
| KNSA | $93.86 | +6.25% | 7.4B | 72.15 | $1.30 | N/A |
| LQDA | $44.40 | -0.20% | 4B | 32.41 | $1.37 | N/A |
| PBH | $42.98 | -3.02% | 2B | 9.72 | $4.42 | N/A |
| HROWL | $25.61 | +0.19% | 1.4B | N/A | N/A | N/A |
| HROWM | $26.03 | -0.08% | 1.3B | N/A | N/A | N/A |
| HELP | $8.96 | +6.79% | 554.1M | -2.15 | -$4.16 | N/A |
Stock Comparison
Royalty Pharma plc (NASDAQ: RPRX)
LTGO vs RPRX Comparison November 2026
Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LTGO stands at 756.1M. In comparison, RPRX has a market cap of 30B. Regarding current trading prices, LTGO is priced at $12.60 on the NASDAQ, while RPRX trades at $67.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LTGO currently has a P/E ratio of -4.99, whereas RPRX's P/E ratio is 12.82. In terms of profitability, LTGO's ROE is N/A, compared to RPRX's ROE of +0.10%. Regarding short-term risk, LTGO is more volatile compared to RPRX. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check RPRX's competition here
Walgreens Boots Alliance, Inc. (NASDAQ: WBA)
LTGO vs WBA Comparison November 2026
Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LTGO stands at 756.1M. In comparison, WBA has a market cap of 10.4B. Regarding current trading prices, LTGO is priced at $12.60 on the NASDAQ, while WBA trades at $11.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LTGO currently has a P/E ratio of -4.99, whereas WBA's P/E ratio is -1.64. In terms of profitability, LTGO's ROE is N/A, compared to WBA's ROE of -0.57%. Regarding short-term risk, LTGO is more volatile compared to WBA. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check WBA's competition here
Corcept Therapeutics Incorporated (NASDAQ: CORT)
LTGO vs CORT Comparison November 2026
Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LTGO stands at 756.1M. In comparison, CORT has a market cap of 7.9B. Regarding current trading prices, LTGO is priced at $12.60 on the NASDAQ, while CORT trades at $72.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LTGO currently has a P/E ratio of -4.99, whereas CORT's P/E ratio is 207.83. In terms of profitability, LTGO's ROE is N/A, compared to CORT's ROE of +0.23%. Regarding short-term risk, LTGO is more volatile compared to CORT. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check CORT's competition here
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA)
LTGO vs KNSA Comparison November 2026
Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LTGO stands at 756.1M. In comparison, KNSA has a market cap of 7.4B. Regarding current trading prices, LTGO is priced at $12.60 on the NASDAQ, while KNSA trades at $93.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LTGO currently has a P/E ratio of -4.99, whereas KNSA's P/E ratio is 72.15. In terms of profitability, LTGO's ROE is N/A, compared to KNSA's ROE of +0.17%. Regarding short-term risk, LTGO is more volatile compared to KNSA. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check KNSA's competition here
Liquidia Corporation (NASDAQ: LQDA)
LTGO vs LQDA Comparison November 2026
Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LTGO stands at 756.1M. In comparison, LQDA has a market cap of 4B. Regarding current trading prices, LTGO is priced at $12.60 on the NASDAQ, while LQDA trades at $44.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LTGO currently has a P/E ratio of -4.99, whereas LQDA's P/E ratio is 32.41. In terms of profitability, LTGO's ROE is N/A, compared to LQDA's ROE of +1.50%. Regarding short-term risk, LTGO is more volatile compared to LQDA. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check LQDA's competition here
Prestige Consumer Healthcare Inc. (NYSE: PBH)
LTGO vs PBH Comparison November 2026
Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LTGO stands at 756.1M. In comparison, PBH has a market cap of 2B. Regarding current trading prices, LTGO is priced at $12.60 on the NASDAQ, while PBH trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LTGO currently has a P/E ratio of -4.99, whereas PBH's P/E ratio is 9.72. In terms of profitability, LTGO's ROE is N/A, compared to PBH's ROE of +0.08%. Regarding short-term risk, LTGO is more volatile compared to PBH. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check PBH's competition here
Harrow Health, Inc. 8.625% Senior Notes due 2026 (NASDAQ: HROWL)
LTGO vs HROWL Comparison November 2026
Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LTGO stands at 756.1M. In comparison, HROWL has a market cap of 1.4B. Regarding current trading prices, LTGO is priced at $12.60 on the NASDAQ, while HROWL trades at $25.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LTGO currently has a P/E ratio of -4.99, whereas HROWL's P/E ratio is N/A. In terms of profitability, LTGO's ROE is N/A, compared to HROWL's ROE of -1.04%. Regarding short-term risk, LTGO is more volatile compared to HROWL. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check HROWL's competition here
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM)
LTGO vs HROWM Comparison November 2026
Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LTGO stands at 756.1M. In comparison, HROWM has a market cap of 1.3B. Regarding current trading prices, LTGO is priced at $12.60 on the NASDAQ, while HROWM trades at $26.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LTGO currently has a P/E ratio of -4.99, whereas HROWM's P/E ratio is N/A. In terms of profitability, LTGO's ROE is N/A, compared to HROWM's ROE of -1.04%. Regarding short-term risk, LTGO is more volatile compared to HROWM. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check HROWM's competition here
Helus Pharma Inc. (NASDAQ: HELP)
LTGO vs HELP Comparison November 2026
Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LTGO stands at 756.1M. In comparison, HELP has a market cap of 554.1M. Regarding current trading prices, LTGO is priced at $12.60 on the NASDAQ, while HELP trades at $8.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LTGO currently has a P/E ratio of -4.99, whereas HELP's P/E ratio is -2.15. In terms of profitability, LTGO's ROE is N/A, compared to HELP's ROE of -0.71%. Regarding short-term risk, LTGO is more volatile compared to HELP. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check HELP's competition here
Sinovac Biotech Ltd. (NASDAQ: SVA)
LTGO vs SVA Comparison November 2026
Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LTGO stands at 756.1M. In comparison, SVA has a market cap of 464.9M. Regarding current trading prices, LTGO is priced at $12.60 on the NASDAQ, while SVA trades at $6.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LTGO currently has a P/E ratio of -4.99, whereas SVA's P/E ratio is -5.68. In terms of profitability, LTGO's ROE is N/A, compared to SVA's ROE of -0.01%. Regarding short-term risk, LTGO is more volatile compared to SVA. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check SVA's competition here
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL)
LTGO vs CUVL Comparison November 2026
Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LTGO stands at 756.1M. In comparison, CUVL has a market cap of 257.5M. Regarding current trading prices, LTGO is priced at $12.60 on the NASDAQ, while CUVL trades at $5.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LTGO currently has a P/E ratio of -4.99, whereas CUVL's P/E ratio is 11.00. In terms of profitability, LTGO's ROE is N/A, compared to CUVL's ROE of N/A. Regarding short-term risk, LTGO is more volatile compared to CUVL. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check CUVL's competition here
High Tide Inc. (NASDAQ: HITI)
LTGO vs HITI Comparison November 2026
Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LTGO stands at 756.1M. In comparison, HITI has a market cap of 235.3M. Regarding current trading prices, LTGO is priced at $12.60 on the NASDAQ, while HITI trades at $2.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LTGO currently has a P/E ratio of -4.99, whereas HITI's P/E ratio is -9.75. In terms of profitability, LTGO's ROE is N/A, compared to HITI's ROE of -0.36%. Regarding short-term risk, LTGO is more volatile compared to HITI. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check HITI's competition here
Electra Therapeutics Inc. (NASDAQ: ETRA)
LTGO vs ETRA Comparison November 2026
Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LTGO stands at 756.1M. In comparison, ETRA has a market cap of 164.6M. Regarding current trading prices, LTGO is priced at $12.60 on the NASDAQ, while ETRA trades at $7.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LTGO currently has a P/E ratio of -4.99, whereas ETRA's P/E ratio is -2.93. In terms of profitability, LTGO's ROE is N/A, compared to ETRA's ROE of N/A. Regarding short-term risk, LTGO is more volatile compared to ETRA. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check ETRA's competition here
TRex Bio Inc. (NASDAQ: TRXB)
LTGO vs TRXB Comparison November 2026
Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LTGO stands at 756.1M. In comparison, TRXB has a market cap of 110.7M. Regarding current trading prices, LTGO is priced at $12.60 on the NASDAQ, while TRXB trades at $13.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LTGO currently has a P/E ratio of -4.99, whereas TRXB's P/E ratio is -5.38. In terms of profitability, LTGO's ROE is N/A, compared to TRXB's ROE of N/A. Regarding short-term risk, LTGO is more volatile compared to TRXB. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check TRXB's competition here
Atlantic International Corp. (NASDAQ: ATLN)
LTGO vs ATLN Comparison November 2026
Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LTGO stands at 756.1M. In comparison, ATLN has a market cap of 68.6M. Regarding current trading prices, LTGO is priced at $12.60 on the NASDAQ, while ATLN trades at $0.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LTGO currently has a P/E ratio of -4.99, whereas ATLN's P/E ratio is -0.68. In terms of profitability, LTGO's ROE is N/A, compared to ATLN's ROE of -83.20%. Regarding short-term risk, LTGO is more volatile compared to ATLN. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check ATLN's competition here
Citius Oncology, Inc. (NASDAQ: CTOR)
LTGO vs CTOR Comparison November 2026
Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LTGO stands at 756.1M. In comparison, CTOR has a market cap of 47.3M. Regarding current trading prices, LTGO is priced at $12.60 on the NASDAQ, while CTOR trades at $0.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LTGO currently has a P/E ratio of -4.99, whereas CTOR's P/E ratio is -1.08. In terms of profitability, LTGO's ROE is N/A, compared to CTOR's ROE of -1.03%. Regarding short-term risk, LTGO is more volatile compared to CTOR. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check CTOR's competition here
Retension Pharmaceuticals Inc. (NASDAQ: RTSN)
LTGO vs RTSN Comparison November 2026
Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LTGO stands at 756.1M. In comparison, RTSN has a market cap of 41M. Regarding current trading prices, LTGO is priced at $12.60 on the NASDAQ, while RTSN trades at $11.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LTGO currently has a P/E ratio of -4.99, whereas RTSN's P/E ratio is -4.19. In terms of profitability, LTGO's ROE is N/A, compared to RTSN's ROE of N/A. Regarding short-term risk, LTGO is more volatile compared to RTSN. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check RTSN's competition here
Rite Aid Corporation (NYSE: RAD)
LTGO vs RAD Comparison November 2026
Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LTGO stands at 756.1M. In comparison, RAD has a market cap of 36.8M. Regarding current trading prices, LTGO is priced at $12.60 on the NASDAQ, while RAD trades at $0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LTGO currently has a P/E ratio of -4.99, whereas RAD's P/E ratio is -0.05. In terms of profitability, LTGO's ROE is N/A, compared to RAD's ROE of +2.76%. Regarding short-term risk, LTGO is more volatile compared to RAD. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check RAD's competition here
Damora Therapeutics, Inc. (NASDAQ: GLTO)
LTGO vs GLTO Comparison November 2026
Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LTGO stands at 756.1M. In comparison, GLTO has a market cap of 34.5M. Regarding current trading prices, LTGO is priced at $12.60 on the NASDAQ, while GLTO trades at $21.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LTGO currently has a P/E ratio of -4.99, whereas GLTO's P/E ratio is -1.78. In terms of profitability, LTGO's ROE is N/A, compared to GLTO's ROE of -0.66%. Regarding short-term risk, LTGO is more volatile compared to GLTO. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check GLTO's competition here
Cosmos Health Inc. (NASDAQ: COSM)
LTGO vs COSM Comparison November 2026
Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LTGO stands at 756.1M. In comparison, COSM has a market cap of 30.8M. Regarding current trading prices, LTGO is priced at $12.60 on the NASDAQ, while COSM trades at $0.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LTGO currently has a P/E ratio of -4.99, whereas COSM's P/E ratio is -0.41. In terms of profitability, LTGO's ROE is N/A, compared to COSM's ROE of -1.19%. Regarding short-term risk, LTGO is more volatile compared to COSM. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check COSM's competition here
Nasus Pharma Ltd. (AMEX: NSRX)
LTGO vs NSRX Comparison November 2026
Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LTGO stands at 756.1M. In comparison, NSRX has a market cap of 24.4M. Regarding current trading prices, LTGO is priced at $12.60 on the NASDAQ, while NSRX trades at $2.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LTGO currently has a P/E ratio of -4.99, whereas NSRX's P/E ratio is -3.93. In terms of profitability, LTGO's ROE is N/A, compared to NSRX's ROE of -1.59%. Regarding short-term risk, LTGO is more volatile compared to NSRX. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check NSRX's competition here
SCYNEXIS, Inc. (NASDAQ: SCYX)
LTGO vs SCYX Comparison November 2026
Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LTGO stands at 756.1M. In comparison, SCYX has a market cap of 22M. Regarding current trading prices, LTGO is priced at $12.60 on the NASDAQ, while SCYX trades at $3.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LTGO currently has a P/E ratio of -4.99, whereas SCYX's P/E ratio is -1.02. In terms of profitability, LTGO's ROE is N/A, compared to SCYX's ROE of -0.19%. Regarding short-term risk, LTGO is more volatile compared to SCYX. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check SCYX's competition here
Pomdoctor Limited (NASDAQ: POM)
LTGO vs POM Comparison November 2026
Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LTGO stands at 756.1M. In comparison, POM has a market cap of 15.5M. Regarding current trading prices, LTGO is priced at $12.60 on the NASDAQ, while POM trades at $1.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LTGO currently has a P/E ratio of -4.99, whereas POM's P/E ratio is -0.26. In terms of profitability, LTGO's ROE is N/A, compared to POM's ROE of +0.80%. Regarding short-term risk, LTGO is less volatile compared to POM. This indicates lower risk in terms of short-term price fluctuations for LTGO.Check POM's competition here
Biofrontera Inc. (NASDAQ: BFRI)
LTGO vs BFRI Comparison November 2026
Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LTGO stands at 756.1M. In comparison, BFRI has a market cap of 12.2M. Regarding current trading prices, LTGO is priced at $12.60 on the NASDAQ, while BFRI trades at $0.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LTGO currently has a P/E ratio of -4.99, whereas BFRI's P/E ratio is -1.49. In terms of profitability, LTGO's ROE is N/A, compared to BFRI's ROE of -1.28%. Regarding short-term risk, LTGO is more volatile compared to BFRI. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check BFRI's competition here
Azora Therapeutics, Inc. (NASDAQ: AZR)
LTGO vs AZR Comparison November 2026
Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LTGO stands at 756.1M. In comparison, AZR has a market cap of 10.4M. Regarding current trading prices, LTGO is priced at $12.60 on the NASDAQ, while AZR trades at $4.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LTGO currently has a P/E ratio of -4.99, whereas AZR's P/E ratio is -0.24. In terms of profitability, LTGO's ROE is N/A, compared to AZR's ROE of N/A. Regarding short-term risk, LTGO is more volatile compared to AZR. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check AZR's competition here
China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD)
LTGO vs CJJD Comparison November 2026
Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LTGO stands at 756.1M. In comparison, CJJD has a market cap of 9.9M. Regarding current trading prices, LTGO is priced at $12.60 on the NASDAQ, while CJJD trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LTGO currently has a P/E ratio of -4.99, whereas CJJD's P/E ratio is -0.46. In terms of profitability, LTGO's ROE is N/A, compared to CJJD's ROE of -0.25%. Regarding short-term risk, LTGO is more volatile compared to CJJD. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check CJJD's competition here
SunLink Health Systems, Inc. (AMEX: SSY)
LTGO vs SSY Comparison November 2026
Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LTGO stands at 756.1M. In comparison, SSY has a market cap of 7.9M. Regarding current trading prices, LTGO is priced at $12.60 on the NASDAQ, while SSY trades at $1.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LTGO currently has a P/E ratio of -4.99, whereas SSY's P/E ratio is -2.86. In terms of profitability, LTGO's ROE is N/A, compared to SSY's ROE of -0.09%. Regarding short-term risk, LTGO is more volatile compared to SSY. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check SSY's competition here
Scienture Holdings, Inc. (NASDAQ: SCNX)
LTGO vs SCNX Comparison November 2026
Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LTGO stands at 756.1M. In comparison, SCNX has a market cap of 5.1M. Regarding current trading prices, LTGO is priced at $12.60 on the NASDAQ, while SCNX trades at $3.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LTGO currently has a P/E ratio of -4.99, whereas SCNX's P/E ratio is -1.49. In terms of profitability, LTGO's ROE is N/A, compared to SCNX's ROE of -0.54%. Regarding short-term risk, LTGO is more volatile compared to SCNX. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check SCNX's competition here
Cerenome, Inc. (NASDAQ: CNSY)
LTGO vs CNSY Comparison November 2026
Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LTGO stands at 756.1M. In comparison, CNSY has a market cap of 4.9M. Regarding current trading prices, LTGO is priced at $12.60 on the NASDAQ, while CNSY trades at $0.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LTGO currently has a P/E ratio of -4.99, whereas CNSY's P/E ratio is -0.15. In terms of profitability, LTGO's ROE is N/A, compared to CNSY's ROE of -3.94%. Regarding short-term risk, LTGO is more volatile compared to CNSY. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check CNSY's competition here
Bio Green Med Solution, Inc. (NASDAQ: BGMS)
LTGO vs BGMS Comparison November 2026
Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LTGO stands at 756.1M. In comparison, BGMS has a market cap of 4.7M. Regarding current trading prices, LTGO is priced at $12.60 on the NASDAQ, while BGMS trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LTGO currently has a P/E ratio of -4.99, whereas BGMS's P/E ratio is -0.24. In terms of profitability, LTGO's ROE is N/A, compared to BGMS's ROE of -0.32%. Regarding short-term risk, LTGO is more volatile compared to BGMS. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check BGMS's competition here
MedAvail Holdings, Inc. (NASDAQ: MDVL)
LTGO vs MDVL Comparison November 2026
Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LTGO stands at 756.1M. In comparison, MDVL has a market cap of 2.9M. Regarding current trading prices, LTGO is priced at $12.60 on the NASDAQ, while MDVL trades at $1.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LTGO currently has a P/E ratio of -4.99, whereas MDVL's P/E ratio is -0.05. In terms of profitability, LTGO's ROE is N/A, compared to MDVL's ROE of -2.39%. Regarding short-term risk, LTGO is less volatile compared to MDVL. This indicates lower risk in terms of short-term price fluctuations for LTGO.Check MDVL's competition here
Eocene Ltd. (NASDAQ: EOCN)
LTGO vs EOCN Comparison November 2026
Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LTGO stands at 756.1M. In comparison, EOCN has a market cap of 2.7M. Regarding current trading prices, LTGO is priced at $12.60 on the NASDAQ, while EOCN trades at $2.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LTGO currently has a P/E ratio of -4.99, whereas EOCN's P/E ratio is -0.19. In terms of profitability, LTGO's ROE is N/A, compared to EOCN's ROE of N/A. Regarding short-term risk, LTGO is more volatile compared to EOCN. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check EOCN's competition here
ETHZilla Corporation Warrant (NASDAQ: ATNFW)
LTGO vs ATNFW Comparison November 2026
Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LTGO stands at 756.1M. In comparison, ATNFW has a market cap of 2.6M. Regarding current trading prices, LTGO is priced at $12.60 on the NASDAQ, while ATNFW trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LTGO currently has a P/E ratio of -4.99, whereas ATNFW's P/E ratio is N/A. In terms of profitability, LTGO's ROE is N/A, compared to ATNFW's ROE of -2.15%. Regarding short-term risk, LTGO is more volatile compared to ATNFW. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check ATNFW's competition here
Paranovus Entertainment Technology Ltd. (NASDAQ: PAVS)
LTGO vs PAVS Comparison November 2026
Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LTGO stands at 756.1M. In comparison, PAVS has a market cap of 2.5M. Regarding current trading prices, LTGO is priced at $12.60 on the NASDAQ, while PAVS trades at $2.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LTGO currently has a P/E ratio of -4.99, whereas PAVS's P/E ratio is -0.03. In terms of profitability, LTGO's ROE is N/A, compared to PAVS's ROE of -0.46%. Regarding short-term risk, LTGO is more volatile compared to PAVS. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check PAVS's competition here
Bio Green Med Solution, Inc. (NASDAQ: BGMSP)
LTGO vs BGMSP Comparison November 2026
Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LTGO stands at 756.1M. In comparison, BGMSP has a market cap of 2.4M. Regarding current trading prices, LTGO is priced at $12.60 on the NASDAQ, while BGMSP trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LTGO currently has a P/E ratio of -4.99, whereas BGMSP's P/E ratio is -0.84. In terms of profitability, LTGO's ROE is N/A, compared to BGMSP's ROE of -0.32%. Regarding short-term risk, LTGO is more volatile compared to BGMSP. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check BGMSP's competition here
AstraZeneca PLC ADRhedged (AMEX: AZNH)
LTGO vs AZNH Comparison November 2026
Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LTGO stands at 756.1M. In comparison, AZNH has a market cap of 1.6M. Regarding current trading prices, LTGO is priced at $12.60 on the NASDAQ, while AZNH trades at $53.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LTGO currently has a P/E ratio of -4.99, whereas AZNH's P/E ratio is 38.35. In terms of profitability, LTGO's ROE is N/A, compared to AZNH's ROE of +0.00%. Regarding short-term risk, LTGO is more volatile compared to AZNH. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check AZNH's competition here
Aspire Biopharma Holdings, Inc. (NASDAQ: ASBP)
LTGO vs ASBP Comparison November 2026
Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LTGO stands at 756.1M. In comparison, ASBP has a market cap of 920.7K. Regarding current trading prices, LTGO is priced at $12.60 on the NASDAQ, while ASBP trades at $8.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LTGO currently has a P/E ratio of -4.99, whereas ASBP's P/E ratio is -0.34. In terms of profitability, LTGO's ROE is N/A, compared to ASBP's ROE of +19.93%. Regarding short-term risk, LTGO is more volatile compared to ASBP. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check ASBP's competition here
Biofrontera Inc. (NASDAQ: BFRIW)
LTGO vs BFRIW Comparison November 2026
Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LTGO stands at 756.1M. In comparison, BFRIW has a market cap of 796.7K. Regarding current trading prices, LTGO is priced at $12.60 on the NASDAQ, while BFRIW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LTGO currently has a P/E ratio of -4.99, whereas BFRIW's P/E ratio is N/A. In terms of profitability, LTGO's ROE is N/A, compared to BFRIW's ROE of -1.28%. Regarding short-term risk, LTGO is less volatile compared to BFRIW. This indicates lower risk in terms of short-term price fluctuations for LTGO.Check BFRIW's competition here
Leafly Holdings, Inc. (NASDAQ: LFLYW)
LTGO vs LFLYW Comparison November 2026
Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LTGO stands at 756.1M. In comparison, LFLYW has a market cap of 299.9K. Regarding current trading prices, LTGO is priced at $12.60 on the NASDAQ, while LFLYW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LTGO currently has a P/E ratio of -4.99, whereas LFLYW's P/E ratio is -0.00. In terms of profitability, LTGO's ROE is N/A, compared to LFLYW's ROE of +0.42%. Regarding short-term risk, LTGO is more volatile compared to LFLYW. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check LFLYW's competition here
Aspire Biopharma Holdings, Inc. (NASDAQ: ASBPW)
LTGO vs ASBPW Comparison November 2026
Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LTGO stands at 756.1M. In comparison, ASBPW has a market cap of 196.7K. Regarding current trading prices, LTGO is priced at $12.60 on the NASDAQ, while ASBPW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LTGO currently has a P/E ratio of -4.99, whereas ASBPW's P/E ratio is N/A. In terms of profitability, LTGO's ROE is N/A, compared to ASBPW's ROE of +19.93%. Regarding short-term risk, LTGO is less volatile compared to ASBPW. This indicates lower risk in terms of short-term price fluctuations for LTGO.Check ASBPW's competition here
ProPhase Labs, Inc. (NASDAQ: PRPH)
LTGO vs PRPH Comparison November 2026
Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LTGO stands at 756.1M. In comparison, PRPH has a market cap of 82.8K. Regarding current trading prices, LTGO is priced at $12.60 on the NASDAQ, while PRPH trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LTGO currently has a P/E ratio of -4.99, whereas PRPH's P/E ratio is N/A. In terms of profitability, LTGO's ROE is N/A, compared to PRPH's ROE of -13.59%. Regarding short-term risk, LTGO is more volatile compared to PRPH. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check PRPH's competition here
Shire plc (NASDAQ: SHPG)
LTGO vs SHPG Comparison November 2026
Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LTGO stands at 756.1M. In comparison, SHPG has a market cap of 0. Regarding current trading prices, LTGO is priced at $12.60 on the NASDAQ, while SHPG trades at $179.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LTGO currently has a P/E ratio of -4.99, whereas SHPG's P/E ratio is 11.35. In terms of profitability, LTGO's ROE is N/A, compared to SHPG's ROE of +0.13%. Regarding short-term risk, LTGO is more volatile compared to SHPG. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check SHPG's competition here
POZEN Inc. (NASDAQ: POZN)
LTGO vs POZN Comparison November 2026
Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LTGO stands at 756.1M. In comparison, POZN has a market cap of 0. Regarding current trading prices, LTGO is priced at $12.60 on the NASDAQ, while POZN trades at $5.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LTGO currently has a P/E ratio of -4.99, whereas POZN's P/E ratio is N/A. In terms of profitability, LTGO's ROE is N/A, compared to POZN's ROE of +0.61%. Regarding short-term risk, LTGO is more volatile compared to POZN. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check POZN's competition here
Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD)
LTGO vs CPD Comparison November 2026
Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LTGO stands at 756.1M. In comparison, CPD has a market cap of 0. Regarding current trading prices, LTGO is priced at $12.60 on the NASDAQ, while CPD trades at $5.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LTGO currently has a P/E ratio of -4.99, whereas CPD's P/E ratio is N/A. In terms of profitability, LTGO's ROE is N/A, compared to CPD's ROE of N/A. Regarding short-term risk, LTGO is more volatile compared to CPD. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check CPD's competition here
Impax Laboratories, Inc. (NASDAQ: IPXL)
LTGO vs IPXL Comparison November 2026
Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LTGO stands at 756.1M. In comparison, IPXL has a market cap of 0. Regarding current trading prices, LTGO is priced at $12.60 on the NASDAQ, while IPXL trades at $18.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LTGO currently has a P/E ratio of -4.99, whereas IPXL's P/E ratio is -10.11. In terms of profitability, LTGO's ROE is N/A, compared to IPXL's ROE of -1.16%. Regarding short-term risk, LTGO is more volatile compared to IPXL. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check IPXL's competition here
Express Scripts Holding Company (NASDAQ: ESRX)
LTGO vs ESRX Comparison November 2026
Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LTGO stands at 756.1M. In comparison, ESRX has a market cap of 0. Regarding current trading prices, LTGO is priced at $12.60 on the NASDAQ, while ESRX trades at $92.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LTGO currently has a P/E ratio of -4.99, whereas ESRX's P/E ratio is 10.69. In terms of profitability, LTGO's ROE is N/A, compared to ESRX's ROE of +0.26%. Regarding short-term risk, LTGO is more volatile compared to ESRX. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check ESRX's competition here
Orexigen Therapeutics, Inc. (NASDAQ: OREX)
LTGO vs OREX Comparison November 2026
Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LTGO stands at 756.1M. In comparison, OREX has a market cap of 0. Regarding current trading prices, LTGO is priced at $12.60 on the NASDAQ, while OREX trades at $0.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LTGO currently has a P/E ratio of -4.99, whereas OREX's P/E ratio is -0.14. In terms of profitability, LTGO's ROE is N/A, compared to OREX's ROE of -0.54%. Regarding short-term risk, LTGO is less volatile compared to OREX. This indicates lower risk in terms of short-term price fluctuations for LTGO.Check OREX's competition here